Apertura Appoints Gene Therapy Executive Joseph La Barge as Chief Executive Officer
La Barge joins Apertura with over 20 years of experience in building and operating life-science companies. Most recently, he served as Chief Business Officer of Spark Therapeutics, where he was one of the earliest employees and led the growth of the company through its acquisition by Roche for $4.8 billion in December 2019.
Apertura Announces Fit4Function AAV Capsid Engineering Platform and In Vivo Proof-of-Concept Data to Be Presented at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
Apertura Gene Therapy announced that its academic collaborators will present findings on the Fit4Function AAV capsid engineering platform and non-human primate proof-of-concept data at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), being held virtually and in Washington, D.C., from May 16–19, 2022.
Apertura Gene Therapy Launches with $67M Series A Financing from Deerfield and an Innovative Technology Platform to Develop Genetic Medicines
Founded on platform technologies developed by Broad Institute of MIT and Harvard and Harvard Medical School Investigators